Alexandra Pender

690 total citations
25 papers, 385 citations indexed

About

Alexandra Pender is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Alexandra Pender has authored 25 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Alexandra Pender's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Genomics and Diagnostics (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Alexandra Pender is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Genomics and Diagnostics (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Alexandra Pender collaborates with scholars based in United Kingdom, Canada and United States. Alexandra Pender's co-authors include Robin L. Jones, Christopher A. McCulloch, Yuanyi Feng, Tiina Kainulainen, Mario D’Addario, Seth M. Pollack, Nicolas Charbonnel, Gillian M. Fraser, Christina Kahramanoglou and Cheryl Ho and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Alexandra Pender

25 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexandra Pender United Kingdom 10 156 119 115 70 65 25 385
Stephen P. Remillard United States 11 285 1.8× 203 1.7× 106 0.9× 63 0.9× 64 1.0× 14 565
Johan O. Paulsson Sweden 15 181 1.2× 42 0.4× 113 1.0× 172 2.5× 51 0.8× 24 523
Stéphanie Torrino France 12 390 2.5× 52 0.4× 79 0.7× 53 0.8× 84 1.3× 15 610
Srinivas Mullapudi United States 10 302 1.9× 17 0.1× 57 0.5× 56 0.8× 43 0.7× 12 417
John R. Christin United States 9 184 1.2× 48 0.4× 151 1.3× 28 0.4× 77 1.2× 16 426
Kyeong Man Hong South Korea 12 352 2.3× 140 1.2× 171 1.5× 30 0.4× 173 2.7× 15 615
Jürgen Oberstraß Germany 6 283 1.8× 19 0.2× 50 0.4× 50 0.7× 109 1.7× 8 423
Kazi R. Fattah United States 11 589 3.8× 45 0.4× 255 2.2× 56 0.8× 109 1.7× 12 675
Devin Bready United States 7 276 1.8× 35 0.3× 63 0.5× 23 0.3× 121 1.9× 11 449
Maren Cam United States 10 194 1.2× 107 0.9× 161 1.4× 51 0.7× 97 1.5× 20 407

Countries citing papers authored by Alexandra Pender

Since Specialization
Citations

This map shows the geographic impact of Alexandra Pender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Pender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Pender more than expected).

Fields of papers citing papers by Alexandra Pender

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra Pender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Pender. The network helps show where Alexandra Pender may publish in the future.

Co-authorship network of co-authors of Alexandra Pender

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Pender. A scholar is included among the top collaborators of Alexandra Pender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Pender. Alexandra Pender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leung, Bonnie, et al.. (2023). Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current Oncology. 30(6). 5299–5308. 3 indexed citations
2.
Edner, Natalie M., Elisavet Ntavli, Lina Petersone, et al.. (2023). Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. PubMed. 3(1). ltad001–ltad001. 4 indexed citations
3.
4.
Titmuss, Emma, Alexandra Pender, James T. Topham, et al.. (2022). The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. Journal of Molecular Diagnostics. 24(6). 609–618. 7 indexed citations
5.
Jones, Lauren, et al.. (2022). Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing. Current Oncology. 29(11). 8686–8692. 5 indexed citations
6.
Batty, Paul, David Hurlbut, Junko Ishida, et al.. (2022). Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A. Blood. 140(25). 2672–2683. 22 indexed citations
7.
Pender, Alexandra, et al.. (2021). Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world. Cancer Medicine. 11(1). 86–93. 23 indexed citations
8.
Pender, Alexandra, Curtis Hughesman, Tracy Tucker, et al.. (2020). EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes. Translational Lung Cancer Research. 9(4). 1084–1092. 8 indexed citations
9.
Pender, Alexandra, Elizabeth J. Davis, Christina Messiou, et al.. (2018). Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Medical Oncology. 35(10). 131–131. 13 indexed citations
10.
Pender, Alexandra, et al.. (2017). Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma. SHILAP Revista de lepidopterología. 4 indexed citations
11.
Pender, Alexandra & Robin L. Jones. (2017). Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma. Clinical Pharmacology Advances and Applications. Volume 9. 159–164. 7 indexed citations
12.
Pender, Alexandra & Robin L. Jones. (2017). Olaratumab for the Treatment of Soft-Tissue Sarcoma. Future Oncology. 13(24). 2151–2157. 2 indexed citations
13.
Pender, Alexandra, Sareena Rana, Elisa Izquierdo, et al.. (2016). 3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice. Lung Cancer. 91. S2–S2. 1 indexed citations
14.
Pender, Alexandra, Isaac García-Murillas, Sareena Rana, et al.. (2015). Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE. 10(9). e0139074–e0139074. 48 indexed citations
15.
Pender, Alexandra & Sanjay Popat. (2014). Understanding lung cancer molecular subtypes. Clinical Practice. 11(4). 441–453. 2 indexed citations
16.
Pender, Alexandra, et al.. (2013). 33 Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC). Lung Cancer. 79. S12–S12. 1 indexed citations
17.
Fisher, Rosalie, Alexandra Pender, Kiruthikah Thillai, et al.. (2012). Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation. SHILAP Revista de lepidopterología. 2. 155–155. 18 indexed citations
18.
Pender, Alexandra, et al.. (2011). Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma.. Journal of Clinical Oncology. 29(15_suppl). e15175–e15175. 1 indexed citations
19.
20.
Kainulainen, Tiina, et al.. (2002). Cell Death and Mechanoprotection by Filamin A in Connective Tissues after Challenge by Applied Tensile Forces. Journal of Biological Chemistry. 277(24). 21998–22009. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen P. Remillard Breakdown of academic impact, for papers by Johan O. Paulsson Breakdown of academic impact, for papers by Stéphanie Torrino Breakdown of academic impact, for papers by Srinivas Mullapudi Breakdown of academic impact, for papers by John R. Christin Breakdown of academic impact, for papers by Kyeong Man Hong Breakdown of academic impact, for papers by Jürgen Oberstraß Breakdown of academic impact, for papers by Kazi R. Fattah Breakdown of academic impact, for papers by Devin Bready Breakdown of academic impact, for papers by Maren Cam
Rankless by CCL
2026